Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02696967
Other study ID # CCLR325X2202
Secondary ID 2016-001387-12
Status Completed
Phase Phase 2
First received
Last updated
Start date May 17, 2016
Est. completion date January 14, 2019

Study information

Verified date September 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 14, 2019
Est. primary completion date January 14, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Male and female patients >18 years of age - Body weight between 50 kg and 140 kg - Cardiac ejection fraction of = 45% assessed within the last 6 months - For PA catheter cohorts, patients who are planned to have a clinically indicated pulmonary artery catheter in place prior to randomization - In the opinion of the investigator, heart failure patients who do not require a change in their dose of acetylcholinesterase (ACE), angiotensin receptor blocker (ARB), ß-blocker, mineralocorticoid receptor antagonist, or diuretic for 24 h after randomization. - At Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) assessment in the supine position after the subject has rested for at least five minutes. Key Exclusion Criteria: - Impaired renal function as indicated by clinically significant abnormal creatinine values (Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 calculated using the Modification of Diet in Renal Disease Study (MDRD) equation) - History of chronic hepatitis of any non-cardiac etiology - History of any active or clinically significant cardiac tachyarrhythmia (such as recurrent atrial fibrillation with rapid ventricular response within the last year) and patients with chronic atrial fibrillation with a pulse rate = 100 bpm - Patients who received an i.v. infusion of a cardiac inotrope (e.g., dobutamine or milrinone) in the last 24 h prior to randomization - Patients with any significant change in their dose of their ACE, ARB, mineralocorticoid receptor antagonist, diuretic, or ß-blocker within the last 12 h - Patients with known significant valvular heart diseases indicated by the following: - severe aortic stenosis (aortic valve area < 1.0 cm2 or peak gradient > 50 mm Hg as determined by echocardiography) - severe mitral stenosis - History of acute coronary syndrome within the last 60 days as determined by both clinical and enzymatic criteria - For echocardiography-based cohorts only, patients admitted to an inpatient setting for acute decompensated heart failure within the last 30 days - For PA catheter cohorts, patients with a pulmonary capillary wedge pressure of <10 mm Hg at Baseline. For echocardiographic cohorts, patients with a lateral E/E' ratio of < 7 on their baseline echocardiogram. For patients in whom a lateral E/E' ratio cannot be determined (e.g., patients in atrial fibrillation), a central venous pressure of < 5 mm Hg on baseline echocardiogram as determined by inferior vena cava criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CLR325
CLR325 Concentrate for solution for infusion
Other:
Placebo
Normal saline

Locations

Country Name City State
Belgium Novartis Investigative Site Aalst
Germany Novartis Investigative Site Greifswald
Germany Novartis Investigative Site Regensburg Bavaria
Netherlands Novartis Investigative Site Amsterdam
Singapore Novartis Investigative Site Singapore
United States Novartis Investigative Site Chicago Illinois
United States Novartis Investigative Site Cleveland Ohio
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Philadelphia Pennsylvania
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site Tacoma Washington

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Netherlands,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients With Adverse Events, Serious Adverse Events and Death Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) in each treatment arm to demonstrate that CLR325 is safe for the treatment of chronic stable heart-failure patients through the monitoring of relevant clinical and laboratory safety parameters. Day 1 to 28
Secondary Pharmacokinetic of CLR325 and CQJ295: Area Under the Plasma Concentration-time Curve From Time Zero to 18 Hours (AUC0-18hr) AUC0-18hr is the area under the plasma concentration-time curve from time zero to 18 hours after the start of CLR325 infusion. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, and 18 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Area Under the Plasma Concentration-time Curve From From Time Zero to 28 Hours (AUC0-28hrs) AUC0-28hr is the area under the plasma concentration-time curve from time zero to 28 hours after the start of CLR325 infusion. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) AUCinf is the area under the plasma concentration-time curve from time zero to infinity. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) AUClast is the area under the plasma concentration-time curve from time zero to the last measurable concentration sampling time. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325: Clearance From Plasma (CL) Following Drug Administration CL is the systemic (or total body) clearance from plasma following CLR325 infusion. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax,ss) Cmax,ss is the observed maximum plasma concentration following drug administration at steady state. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Terminal Elimination Half-life (T1/2) T^1/2 is the elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Time to Reach the Maximum Concentration After Drug Administration (TMax) Tmax is the time to reach maximum plasma concentration after single dose administration. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325: Volume of Distribution at Steady State Following Intravenous Administration (Vss) Vss is the volume of distribution at steady state following intravenous administration. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. 0, 0.5, 3, 5, 8, 10, 12, 18, 20, 24, and 28 hours post start of CLR325 infusion on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Amount of Drug (or Defined Metabolite) Excreted Into the Urine From Time (Ae 0-28 Hours) Ae 0-28 hours is the amount of drug (or defined metabolite) excreted into the urine from time zero to 28 hours after the start of CLR325 infusion. The urine PK parameters were measured using an non-compartmental methods. Only descriptive analysis performed. 0-28 hours on Day 1
Secondary Pharmacokinetic of CLR325 and CQJ295: Renal Clearance From Plasma (CLr) Following Drug Administration CLr is the renal clearance from urine following CLR325 infusion. The urine PK parameters were measured using an non-compartmental methods. Only descriptive analysis performed. 0-28 hours on Day 1
Secondary Number of Patients With Increase in Anti-CLR325 and Anti-apelin Antibodies in Serum Anti-CLR325 anti-apelin antibodies in serum were analyzed predose, Day 10 and Day 28 to determine the immunogenicity of an 18-hour i.v. infusion of CLR325 in heart failure patients. Baseline (BL), Day 10 (D10) and Day 28 (D28)
See also
  Status Clinical Trial Phase
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Recruiting NCT03834155 - Enhancing Cardiac Rehabilitation Through Behavioral Nudges N/A
Withdrawn NCT04507347 - Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus Phase 3
Completed NCT02204449 - Cardiac Rehabilitation Peer Mentorship N/A
Completed NCT00663195 - Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure Phase 4
Completed NCT00664222 - Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF) Phase 4
Completed NCT00663494 - Matrix Metalloproteinase (MMP) in Heart Failure N/A
Recruiting NCT05034549 - Noninvasive Ventilation for Chronic Heart Failure N/A
Recruiting NCT01065194 - Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure Phase 3